Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104403 · ClinicalTrials.gov registry record · Phase 2
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 722
- Enrollment target
NCT00104403: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00104403 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 722 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (443% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00104403, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 722 participants
- Enrollment target
Study Summary
This study was designed to assess the safety and efficacy of different dosages and administration schedules of an investigational agent administered over 3 days when added to standard therapy used in the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Subjects will be asked to complete daily diaries while on study medication. In addition subjects will be required to return to the investigational site several times during the course of the study for follow up safety assessments which may include blood samples for hematology and chemistry evaluations as well as physical exams. A final assessment will be preformed on study Day 20-30 at which time the subject will complete the study.
Interventions
- DRUG Dexamethasone
- DRUG GW679769
- DRUG Ondansetron Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 722 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
What the finished NCT00104403 record still lists
NCT00104403 is an interventional study that assigns participants to a tested intervention. The registered 722 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (443% higher).
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT00104403 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00104403 about?
NCT00104403 is a clinical study titled "Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy". This study was designed to assess the safety and efficacy of different dosages and administration schedules of an investigational agent administered over 3 days when added to standard therapy used in the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Subjects will be aske...
What is the current status of trial NCT00104403?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 722 participants. The study started on 2004-12. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00104403?
The interventions under investigation include: Dexamethasone (DRUG), GW679769 (DRUG), Ondansetron Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00104403?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00104403's enrollment target sits among peer trials
722 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06116149 · 722 participants · NA
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- NCT07088068 · 723 participants · Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia